PointState Capital’s Amicus Therapeutics FOLD Stock Holding History

PointState Capital’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-1,085,900	Closed	-$15.6M	–	178
2017 Q4	$15.6M	Sell	1,085,900 -581,000	-35%	-$7.98M	0.15%	85
2017 Q3	$25.1M	Buy	+1,666,900	New	+$22.1M	0.21%	80
2016 Q2	–	Sell	-150,000	Closed	-$1.27M	–	118
2016 Q1	$1.27M	Buy	+150,000	New	+$1.06M	0.03%	84

Other funds holding FOLD

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PointState Capital's FOLD Position: Q1 2018 in Review

PointState Capital sold out of Amicus Therapeutics (FOLD) in Q1 2018, closing a stake of 1,085,900 shares — an estimated $15.6M sold.

PointState Capital first reported a position in FOLD in Q1 2016 and held it in 3 quarters. The position peaked at $25.1M in Q3 2017. 203 funds tracked by Wall St. Rank hold FOLD as of Q1 2018.

PointState Capital reported no remaining Amicus Therapeutics position as of Q1 2018 after selling out during the quarter.
PointState Capital sold 1,085,900 Amicus Therapeutics shares in Q1 2018, an estimated $15.6M.
PointState Capital first reported a position in Amicus Therapeutics in Q1 2016 and held it in 3 quarters.
PointState Capital's Amicus Therapeutics position peaked at $25.1M in Q3 2017.
203 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2018.

Based on PointState Capital's 13F filing for Q1 2018, filed 15 May 2018.